Five-Year cost-effectiveness of the multidisciplinary risk assessment and management programme–Diabetes mellitus (RAMP- DM)

Diabetes Care

Volumn 41, Issue 2, 2018, Pages 250-257

  Jiao, Fang Fang ^a,b   Cheung Fung, Colman Siu ^a,b   Fai Wan, Eric Yuk ^a,b   Chun Chan, Anca Ka ^a,b   McGhee, Sarah Morag ^c   Ping Kwok, Ruby Lai ^d   Kuen Lam, Cindy Lo ^a,b  

^a Ap Lei Chau Clinic   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d HOSPITAL AUTHORITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALL CAUSE MORTALITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC COMPLICATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PROGRAM COST EFFECTIVENESS; PROGRAM EFFECTIVENESS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK MANAGEMENT; ADOLESCENT; AGED; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; INCIDENCE; INTERDISCIPLINARY RESEARCH; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; PROCEDURES; PROGRAM EVALUATION; PUBLIC HEALTH; RISK FACTOR; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INCIDENCE; INTERDISCIPLINARY RESEARCH; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PRIMARY HEALTH CARE; PROGRAM EVALUATION; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 85041178532     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1149     Document Type: Article

References (40)

1. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium, International Diabetes Federation, 2015
2. Xu Y, Wang L, He J, et al.; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–959
3. American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetesd2017. Diabetes Care 2017;40(Suppl. 1):S48–S56
4. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London, U.K., Royal College of Physicians, 2008
5. Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl. 1):S1–S201
6. Maislos M, Weisman D. Multidisciplinary approach to patients with poorly controlled type 2 diabetes mellitus: a prospective, randomized study. Acta Diabetol 2004;41:44–48
7. Chen MY, Huang WC, Peng YS, et al. Effectiveness of a health promotion programme for farmers and fishermen with type-2 diabetes in Taiwan. J Adv Nurs 2011;67:2060–2067
8. Litaker D, Mion L, Planavsky L, Kippes C, Mehta N, Frolkis J. Physician - nurse practitioner teams in chronic disease management: the impact on costs, clinical effectiveness, and patients’ perception of care. J Interprof Care 2003;17:223–237
9. Mousquès J, Bourgueil Y, Le Fur P, Yilmaz E. Effect of a French experiment of team work between general practitioners and nurses on efficacy and cost of type 2 diabetes patients care. Health Policy 2010;98:131–143
10. Hansen LJ, Siersma V, Beck-Nielsen H, de Fine Olivarius N. Structured personal care of type 2 diabetes: a 19 year follow-up of the study Diabetes Care in General Practice (DCGP). Diabetologia 2013;56:1243–1253
11. Slingerland AS, Herman WH, Redekop WK, Dijkstra RF, Jukema JW, Niessen LW. Stratified patient-centered care in type 2 diabetes: a cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness. Diabetes Care 2013; 36:3054–3061
12. Ritzwoller DP, Sukhanova AS, Glasgow RE, et al. Intervention costs and cost-effectiveness for a multiple-risk-factor diabetes self-management trial for Latinas: economic analysis of ¡Viva Bien! Transl Behav Med 2011;1:427–435
13. Katon W, Russo J, Lin EH, et al. Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. Arch Gen Psychiatry 2012;69:506–514
14. Tao L, Wilson EC, Wareham NJ, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION- UK cluster-randomized controlled trial. Diabet Med 2015;32:907–919
15. Jiao FF, Fung CS, Wong CK, et al. Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP- DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care: a longitudinal comparative study. Cardiovasc Diabetol 2014;13:127
16. Jiao F, Fung CS, Wan YF, et al. Long-term effects of the multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP- DM): a population-based cohort study. Cardiovasc Diabetol 2015;14:105
17. Jiao F, Fung CS, Wan YF, et al. Effectiveness of the multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP- DM) for diabetic microvascular complications: a population-based cohort study. Diabetes Metab 2016;42:424–432
18. Wan EYF, Fung CSC, Jiao FF, et al. Five-year effectiveness of the multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP- DM) on diabetes-related complications and health service usesda population-based and propensity-matched cohort study. Diabetes Care 2018;41:49–59
19. Fung CS, Chin WY, Dai DS, et al. Evaluation of the quality of care of a multi-disciplinary Risk factor Assessment and Management Programme (RAMP) for diabetic patients. BMC Fam Pract 2012;13:116
20. So WY, Raboca J, Sobrepena L, et al.; JADE Program Research Team. Comprehensive risk assessments of diabetic patients from seven Asian countries: the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes 2011;3:109–118
21. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318: 1728–1733
22. Wong CK, Wong WC, Lam CL, et al. Effects of Patient Empowerment Programme (PEP) on clinical outcomes and health service utilization in type 2 diabetes mellitus in primary care: an observational matched cohort study. PLoS One 2014;9: e95328
23. Brown SA. Interventions to promote diabetes self-management: state of the science. Diabetes Educ 1999;25(Suppl.):52–61
24. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 2002;25:1159–1171
25. Gary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ 2003;29:488–501
26. Deakin T, McShane CE, Cade JE, Williams RD. Group based training for self-management strategies in people with type 2 diabetes mellitus. Co-chrane Database Syst Rev 2005;2:CD003417
27. Renders CM, Valk GD, Griffin SJ, Wagner EH, Eijk Van JT, Assendelft WJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care 2001;24:1821–1833
28. Beck J, Greenwood DA, Blanton L, et al.; 2017 Standards Revision Task Force. 2017 National Standards for diabetes self-management education and support. Diabetes Care 2017;40: 1409–1419
29. Ely EK, Gruss SM, Luman ET, et al. A national effort to prevent type 2 diabetes: participant-level evaluation of CDC’s National Diabetes Prevention Program. Diabetes Care 2017;40:1331–1341
30. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378:156–167
31. Chan BS, Tsang MW, Lee VW, Lee KK. Cost of type 2 diabetes mellitus in Hong Kong Chinese. Int J Clin Pharmacol Ther 2007;45:455–468
32. Hospital Authority. HA in focus 2006 [Internet], 2006. Available from http://www.ha.org.hk/ho/corpcomm/focus/2006.pdf. Accessed 15 April 2017
33. Jiao F, Wong CKH, Tang SCW, et al. Annual direct medical costs associated with diabetes-related complications in the event and subsequent years and in subsequent years in Hong Kong. Diabet Med 2017;34:1276–1283
34. Raikou M, McGuire A, Colhoun HM, et al.; CARDS Investigators. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50:733–740
35. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000;320:1373–1378
36. Almbrand B, Johannesson M, Sjöstrand B, Malmberg K, Rydén L. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J 2000;21:733–739
37. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/ DPPOS. Diabetes Care 2012;35:723–730
38. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518–2523
39. Gillett M, Dallosso HM, Dixon S, et al. Delivering the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ 2010; 341:c4093
40. Hospital Authority. Hospital Authority annual report 2013-2014 [Internet]. Available from https://www.ha.org.hk/upload/publication_13/494.pdf. Accessed 15 April 2017